{"id":7201,"date":"2024-11-21T07:30:00","date_gmt":"2024-11-21T07:30:00","guid":{"rendered":"https:\/\/realheart.se\/mfn_news\/new-preclinical-simulation-data-shows-superior-effect-of-realheart-tah-in-regulating-cardiovascular-function-during-sleep\/"},"modified":"2024-11-21T07:30:00","modified_gmt":"2024-11-21T07:30:00","slug":"new-preclinical-simulation-data-shows-superior-effect-of-realheart-tah-in-regulating-cardiovascular-function-during-sleep","status":"publish","type":"mfn_news","link":"https:\/\/realheart.se\/sv\/mfn_news\/new-preclinical-simulation-data-shows-superior-effect-of-realheart-tah-in-regulating-cardiovascular-function-during-sleep\/","title":{"rendered":"New Preclinical Simulation Data Shows Superior Effect of Realheart\u00ae TAH in Regulating Cardiovascular Function During Sleep"},"content":{"rendered":"
\n

V\u00e4ster\u00e5s, Sweden, November 21, 2024 \u2013 Scandinavian Real Heart AB (publ) announces today that the company presented updated safety data from a preclinical study with Realheart\u00ae TAH at the 30th Annual Meeting of ISMCS 2024. At the meeting, the company\u2019s R&D engineer Faisal Zaman was nominated for the Helmut Reul Young Investigator Award, a prestigious award that recognizes ground-breaking innovation.<\/strong><\/p>\n<\/div>\n

\n

Besides presenting positive results from two preclinical studies, earlier communicated in a press release on September 5, Realheart now presented promising results concerning cardiac output during sleep and exercise.<\/p>\n

In the current studies, the performance of Realheart\u00ae TAH was compared to a market-leading product. Simulation results show that Realheart TAH's automatically regulated cardiac output is superior to the market-leading product in adapting to patient needs, both during sleep and exercise.<\/p>\n

\u201cThis is very promising data as it is likely that patients will have a better quality of life if the artificial heart can automatically adapt to the body's activity level. We are committed to developing an artificial heart that mimics the physiological heart as closely as possible, and the research results presented at the ISMCS meeting reveal yet another aspect in which we are successful in this ambition,\u201d said Ina Laura Perkins, CEO of Realheart.<\/p>\n

During ISMCS, Realheart R&D engineer Faisal Zaman was nominated for the Helmut Reul Young Investigator Award for his contributions to the research and development of Realheart\u00ae TAH. The nomination meant that the research results were presented in the opening session of the conference and thus to a packed auditorium.<\/p>\n<\/div>\n

\n

For more information, please contact:<\/strong>
Ina Laura Perkins, CEO
Phone: +46 (0) 70 406 49 21\u00a0
E-mail: inalaura.perkins@realheart.se<\/a>
Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se<\/a><\/p>\n<\/div>\n

\n

About Us<\/strong>
Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. Realheart\u00ae TAH (Total Artificial Heart) is now being evaluated in extensive preclinical trial models ahead of a first clinical study in patients. In the future, artificial hearts may also become an alternative to transplantation for broader groups of patients with severe heart failure. The company's shares are traded on Nasdaq Stockholm First North Growth Market. For more information, visit www.realheart.se<\/a><\/p>\n<\/div>\n

\n

Attachments<\/strong>
New Preclinical Simulation Data Shows Superior Effect of Realheart\u00ae TAH in Regulating Cardiovascular Function During Sleep<\/a><\/p>\n<\/div>\n